Skip to main content
. Author manuscript; available in PMC: 2009 Sep 4.
Published in final edited form as: J Pharmacokinet Pharmacodyn. 2009 Jan 21;36(1):1–18. doi: 10.1007/s10928-008-9107-3

Fig. 4.

Fig. 4

The effect of KETO administration route on AUCR. Predictions incorporated individual subject variability. The notations (TF, TM, SPF, SLM, SLF) represent tablet fasting (a), tablet meal (b), suspension fasting (c), solution meal (d), and solution fasting (e), respectively. The KETO(PO)/MDZ(IV) combination is 800/10 mg and Ki = 0.0037